JoÃo Fernandes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7926104/publications.pdf

Version: 2024-02-01

103	71,188	38660 50	31759 101
papers	citations	h-index	g-index

104	104	104	101696
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants. Pharmaceuticals, 2022, 15, 265.	1.7	25
2	Bioactivity and Bioaccessibility of Bioactive Compounds in Gastrointestinal Digestion of Tomato Bagasse Extracts. Foods, 2022, 11, 1064.	1.9	3
3	Looking Ahead: Health Impact Assessment of Front-of-Pack Nutrition Labelling Schema as a Public Health Measure. International Journal of Environmental Research and Public Health, 2021, 18, 1422.	1.2	6
4	Phytosterols and Novel Triterpenes Recovered from Industrial Fermentation Coproducts Exert In Vitro Anti-Inflammatory Activity in Macrophages. Pharmaceuticals, 2021, 14, 583.	1.7	12
5	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980â€“2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. Lancet, The, 2021, 398, 503-521.	6.3	93
6	Novel Micro- and Nanocellulose-Based Delivery Systems for Liposoluble Compounds. Nanomaterials, 2021, 11, 2593.	1.9	8
7	Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol. BMJ Open, 2021, 11, e055630.	0.8	13
8	The global, regional, and national burden of stomach cancer in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 42-54.	3.7	390
9	The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 17-30.	3.7	1,200
10	Effectiveness of interpretive front-of-pack nutritional labelling schemes on the promotion of healthier food choices: a systematic review. International Journal of Evidence-Based Healthcare, 2020, 18, 24-37.	0.1	25
11	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
12	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	15.2	47
13	Long Pentraxin 3 as a Broader Biomarker for Multiple Risk Factors in End-Stage Renal Disease: Association with All-Cause Mortality. Mediators of Inflammation, 2019, 2019, 1-12.	1.4	15
14	Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients. Renal Failure, 2019, 41, 662-672.	0.8	10
15	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 913-933.	3.7	259
16	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	13.7	161
17	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	1.9	15
18	Health effects of dietary risks in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2019, 393, 1958-1972.	6.3	3,062

#	Article	IF	Citations
19	The Burden of Cardiovascular Diseases Among US States, 1990-2016. JAMA Cardiology, 2018, 3, 375.	3.0	271
20	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
21	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
22	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
23	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
24	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
25	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
26	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
27	Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. Drug Discovery Today, 2018, 23, 1996-2002.	3.2	39
28	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA - Journal of the American Medical Association, 2017, 317, 165.	3.8	1,492
29	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	3.0	194
30	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology, 2017, 3, 524.	3.4	4,254
31	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
32	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017, 377, 13-27.	13.9	5,014
33	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	3.3	306
34	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
35	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
36	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565

#	Article	IF	Citations
37	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
38	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
39	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
40	High Fasting Plasma Glucose, Diabetes, and Its Risk Factors in the Eastern Mediterranean Region, 1990â€“2013: Findings From the Global Burden of Disease Study 2013. Diabetes Care, 2017, 40, 22-29.	4.3	51
41	Recent Patents on Heat Shock Proteins Targeting Antibodies. Recent Patents on Anti-Cancer Drug Discovery, 2017, 12, 48-54.	0.8	7
42	Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. International Journal of Nanomedicine, 2016, Volume 11, 3621-3640.	3.3	48
43	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. International Journal of Molecular Sciences, 2016, 17, 28.	1.8	11
44	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPCIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. Nephrology Dialysis Transplantation, 2016, 31, i194-i194.	0.4	1
45	Renal riskâ€benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model â€“ hypertension, anaemia, inflammation and drug dose. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 343-354.	0.9	10
46	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. Biochimie, 2016, 125, 150-162.	1.3	11
47	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sciences, 2016, 151, 147-156.	2.0	4
48	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
49	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
50	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
51	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
52	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6.3	571
53	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
54	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461

#	Article	IF	Citations
55	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	0.6	6
56	Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. Oncotarget, 2016, 7, 4326-4343.	0.8	37
57	Liver iron is a major regulator of hepcidin gene expression via <scp>BMP/SMAD</scp> pathway in a rat model of chronic renal failure under treatment with high r<scp>H</scp>u<scp>EPO</scp> doses. BioFactors, 2016, 42, 296-306.	2.6	8
58	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. PLoS ONE, 2015, 10, e0124048.	1.1	33
59	The Use of Natural Polysaccharides as Biomaterials. BioMed Research International, 2015, 2015, 1-2.	0.9	7
60	Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. Quality of Life Research, 2015, 24, 1327-1335.	1.5	25
61	Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration. , 2015, 6, 17.		6
62	Protective effect of C. sativa leaf extract against UV mediated-DNA damage in a human keratinocyte cell line. Journal of Photochemistry and Photobiology B: Biology, 2015, 144, 28-34.	1.7	32
63	Effects of the olive oil phenol metabolite 3,4-DHPEA-EDAH₂on human erythrocyte oxidative damage. Food and Function, 2015, 6, 2350-2356.	2.1	9
64	Body Fat Percentage Is a Major Determinant of Total Bilirubin Independently of UGT1A1*28 Polymorphism in Young Obese. PLoS ONE, 2014, 9, e98467.	1.1	22
65	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. BioMed Research International, 2014, 2014, 1-17.	0.9	9
66	Type of Vascular access and Location in Online Hemodiafiltration and its Association with Patient's Perception of Health-Related Quality of Life. Journal of Vascular Access, 2014, 15, 175-182.	0.5	21
67	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 2014, 15, 8979-8997.	1.8	26
68	Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia. BioMed Research International, 2014, 2014, 1-10.	0.9	5
69	Biocompatibility and hemocompatibility of polyvinyl alcohol hydrogel used for vascular grafting-In vitroandin vivostudies. Journal of Biomedical Materials Research - Part A, 2014, 102, n/a-n/a.	2.1	84
70	The effect of olive leaf supplementation on the constituents of blood and oxidative stability of red blood cells. Journal of Functional Foods, 2014, 9, 271-279.	1.6	21
71	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression. , 2014, 5, 356-65.		12
72	Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovascular Diabetology, 2013, 12, 44.	2.7	66

#	Article	IF	Citations
73	The in vitro and in vivo genotoxicity of isotretinoin assessed by cytokinesis blocked micronucleus assay and comet assay. Toxicology in Vitro, 2013, 27, 900-907.	1.1	3
74	Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralenâ€“ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 753, 42-47.	0.9	8
75	Protective Activity of Hydroxytyrosol Metabolites on Erythrocyte Oxidative-Induced Hemolysis. Journal of Agricultural and Food Chemistry, 2013, 61, 6636-6642.	2.4	35
76	Effect of whey protein purity and glycerol content upon physical properties of edible films manufactured therefrom. Food Hydrocolloids, 2013, 30, 110-122.	5.6	360
77	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	0.6	45
78	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 2013, 17, n/a-n/a.	0.4	11
79	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 2013, 35, 1392-1398.	0.8	10
80	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	0.8	4
81	Effect of composition of commercial whey protein preparations upon gelation at various pH values. Food Research International, 2012, 48, 681-689.	2.9	31
82	Antimicrobial activity of edible coatings prepared from whey protein isolate and formulated with various antimicrobial agents. International Dairy Journal, 2012, 25, 132-141.	1.5	55
83	Evaluation of chitoligosaccharides effect upon probiotic bacteria. International Journal of Biological Macromolecules, 2012, 50, 148-152.	3.6	12
84	Study of antimicrobial activity and atomic force microscopy imaging of the action mechanism of cashew tree gum. Carbohydrate Polymers, 2012, 90, 270-274.	5.1	46
85	Features and performance of edible films, obtained from whey protein isolate formulated with antimicrobial compounds. Food Research International, 2012, 45, 351-361.	2.9	120
86	Edible Films and Coatings from Whey Proteins: A Review on Formulation, and on Mechanical and Bioactive Properties. Critical Reviews in Food Science and Nutrition, 2012, 52, 533-552.	5.4	163
87	Evaluation of antimicrobial edible coatings from a whey protein isolate base to improve the shelf life of cheese. Journal of Dairy Science, 2012, 95, 6282-6292.	1.4	110
88	Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model. Marine Drugs, 2012, 10, 2661-2675.	2.2	43
89	Cytotoxicity and genotoxicity of chitooligosaccharides upon lymphocytes. International Journal of Biological Macromolecules, 2011, 49, 433-438.	3.6	24
90	Apoptosis of Peripheral CD4⁺T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. Renal Failure, 2011, 33, 138-143.	0.8	25

#	Article	IF	Citations
91	Animal Model of Implant Capsular Contracture: Effects of Chitosan. Aesthetic Surgery Journal, 2011, 31, 540-550.	0.9	17
92	In vitro studies with â€˜acatalasemicâ€‰keâ€™ erythrocytes and hydrogen peroxide: attention to the formation of lysis resistant erythrocytes. International Journal of Laboratory Hematology, 2010, 32, 127-131.	0.7	2
93	Antioxidant activity of chitooligosaccharides upon two biological systems: Erythrocytes and bacteriophages. Carbohydrate Polymers, 2010, 79, 1101-1106.	5.1	71
94	Powerful Protective Role of 3,4-Dihydroxyphenylethanolâˆ’Elenolic Acid Dialdehyde against Erythrocyte Oxidative-Induced Hemolysis. Journal of Agricultural and Food Chemistry, 2010, 58, 135-140.	2.4	52
95	Anti-Inflammatory Activity of Chitooligosaccharides in Vivo. Marine Drugs, 2010, 8, 1763-1768.	2.2	109
96	Plant aqueous extracts: Antioxidant capacity via haemolysis and bacteriophage P22 protection. Food Control, 2010, 21, 633-638.	2.8	19
97	In vitro screening for anti-microbial activity of chitosans and chitooligosaccharides, aiming at potential uses in functional textiles. Journal of Microbiology and Biotechnology, 2010, 20, 311-318.	0.9	64
98	Effects of olive oil polyphenols on erythrocyte oxidative damage. Molecular Nutrition and Food Research, 2009, 53, 609-616.	1.5	95
99	Study of the antibacterial effects of chitosans on Bacillus cereus (and its spores) by atomic force microscopy imaging and nanoindentation. Ultramicroscopy, 2009, 109, 854-860.	0.8	78
100	Atomic force microscopy study of the antibacterial effects of chitosans on Escherichia coli and Staphylococcus aureus. Ultramicroscopy, 2008, 108, 1128-1134.	0.8	306
101	Antimicrobial effects of chitosans and chitooligosaccharides, upon Staphylococcus aureus and Escherichia coli, in food model systems. Food Microbiology, 2008, 25, 922-928.	2.1	238
102	Effects of Chitooligosaccharides on Human Red Blood Cell Morphology and Membrane Protein Structure. Biomacromolecules, 2008, 9, 3346-3352.	2.6	51
103	The antimicrobial effect of wine on Listeria innocua in a model stomach system. Food Control, 2007, 18, 1477-1483.	2.8	21